Previous 10 | Next 10 |
Hillstream BioPharma (NASDAQ:HILS) spiked before paring gains in the morning hours on Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) granted the Orphan Drug Designation to HSB-1216 for Uveal Melanoma (UM). A type of cancer involving the human eye, Uveal...
- Uveal melanoma is a n aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease - - Evidence implicates ferroptosis, an emerging iron-mediated cell death, as a pathway to effectivel...
Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15 million Initial Public Offering on January 14, 2022 R&D Day to Review Novel Emerging Pipeline on February 24, 2022 BRIDGEWATER, NJ / ACCESSWIRE ...
R&D Day on Thursday February 24, 2022 at 8:00 am ET to highlight emerging pipeline assets and anticipated milestones Business Review on Monday February 14, 2022 to highlight key program developments BRIDGEWATER, NJ / ACCESSWIRE / February 11, 2022 / Hillstream BioPharma, Inc. (...
Shares of Hillstream BioPharma Inc. (NASDAQ:HILS) traded today at $4.22, eclipsing its 52-week high. This new high was reached on below average trading volume as 159,000 shares traded hands, while the average 30-day volume is approximately 588,000 shares. In the past 52 weeks, shares of ...
BRIDGEWATER, NJ / ACCESSWIRE / February 1, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for dru...
Hillstream BioPharma Inc. (NASDAQ:HILS) traded at a new 52-week high today of $4.20. Approximately 159,000 shares have changed hands today, as compared to an average 30-day volume of 546,000 shares. In the past 52 weeks, Hillstream BioPharma Inc. share prices are bracketed by a low of $2...
Collaboration Aims to Identify Novel Chemogenetic Biomarker Profile of HSB-1216 for Solid Tumors Using CRISPR Mediated Genome Editing to Uncover Novel Targets and Gene Regulatory Networks in Ferroptosis / Iron Mediated Cell Death (IMCD) Pathways Further Elucidate the Mechanism of A...
Thanks to continued fear and uncertainty, the stock market is down again today. Whether you’re looking for penny stocks to buy or higher-priced names, it’s clear there’s blood in the streets. Is it time to buy this dip, or should you expect more selling pressure? With t...
The stock market is down today. This can be attributed to various reasons, including global economic conditions, interest rates, and company performance. However, there are also opportunities in times like these. The Dow Jones Industrial Average ETF ( NYSE: DIA ) has fallen by over ...
News, Short Squeeze, Breakout and More Instantly...
Hillstream BioPharma Inc. Company Name:
HILS Stock Symbol:
NASDAQ Market:
Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeu...
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic prur...